Osteogen BONEIN bone & joint support

A Clinical Field Trial Combining Strontium and a Lithothamnion Mineral Complex for Resolution of Developmental Bone Disease in Horses

Osteogen LLC recently conducted a clinical field trial on the use of a combination of Strontium and a Lithothamnion (genus of red marine algae) mineral complex for the resolution of developmental bone disease in horses. The trial was a success and showed promising results for the use of this combination in horses suffering from bone diseases.

Developmental bone disease is a common problem faced by horse owners and trainers worldwide. In many cases, this disease is a result of improper nutrition and management of the horse. However, it can also be influenced by genetic and environmental factors. Once a horse develops a bone disease, the road to recovery is long and challenging, and the treatment options available are limited.

Strontium, a chemical element, has been shown to have positive effects on bone density and bone formation in humans and animals. Lithothamnion, a mineral complex derived from red seaweed, is rich in calcium, magnesium, and other essential minerals that are necessary for optimal bone health.

Osteogen LLC combined Strontium and Lithothamnion to create a unique supplement designed to promote bone health and aid in the resolution of developmental bone diseases in horses.

The field trial started in various Phases. Phase I was a Control Study where horses received the marine mineral complex (Aquamin F) and no Strontium salt for one month. Phase II was were selected horses with issues of concern were given mixture of both a strontium salt (Ranelate) and the marine mineral mixture complex. (Aquamin F). This phase would carry on for approximately one year; late 2021 through 2022. There was a short Reassessment Phase that detailed a small selection of horses and compared blood levels between strontium ranelate and strontium citrate.

At the end of the trial, the horses in the treatment group demonstrated clinical joint eﬀusion and lameness resolution while on the supplementation, which was very unique in the authors experience. And the author was also the attending veterinarian for these cases so it’s doubtful the adjunct therapies were incorporated.

The trial was very informative on not only a possible treatment for sesamoiditis, but also suggested the main causative factor lie with the attaching suspensory branch and its passing the inflammation on to the sesamoid, and not vice versa as has been commonly believed.

Further studies, using advanced sonography which can identify old areas of suspensory ligament desmitis could be helpful in further exploring this area of interest.

The results of the trial are promising and suggest that the combination of Strontium and Lithothamnion can be an effective treatment option for horses suffering from developmental bone disease.

In conclusion, Osteogen’s clinical field trial combining Strontium and the red algae mineral complex for the resolution of developmental bone disease in horses showed promising results. This combination can be a valuable treatment option for horse owners and trainers who are struggling to manage developmental bone diseases in their horses.